Novartis said its BTK inhibitor remibrutinib (also known as Rhapsido for chronic skin hives) succeeded in two phase 3 multiple sclerosis studies, claiming superiority over Aubagio in reducing annualized relapse rates and inflammatory brain lesions. The company did not disclose full data, but emphasized clinically meaningful effects on disability progression and comparable liver safety. Analysts flagged that investors will focus on safety details given prior liver-related limitations seen with parts of the BTK-inhibitor class in MS. Still, a positive efficacy package could reposition remibrutinib for broader MS use, particularly if regulators agree the benefit-risk profile holds across patient populations. Novartis said it plans to share the trial results with health authorities, setting up the next step for regulatory review and labeling discussions.